Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTONEL vs BONIVA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.
Bisphosphonate that inhibits bone resorption via binding to hydroxyapatite and inhibiting osteoclast activity.
Treatment of Paget's disease of bone,Treatment of osteoporosis in postmenopausal women,Prevention of osteoporosis in postmenopausal women,Treatment of glucocorticoid-induced osteoporosis,Off-label: Prevention of bone metastases in some cancers
Treatment and prevention of postmenopausal osteoporosis,Treatment of glucocorticoid-induced osteoporosis
35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.
150 mg orally once monthly; 2.5 mg orally once daily also approved but less commonly used. Administer on empty stomach with plain water (6-8 oz) at least 60 minutes before first food, beverage, or other medications. Do not lie down for 60 minutes after administration.
Terminal elimination half-life: 1.5-2 hours (short for bisphosphonates due to rapid renal clearance); however, bone retention half-life is prolonged (>1 year) due to binding to hydroxyapatite.
Terminal half-life: 10-60 hours (clinical relevant); long terminal half-life (120-720 hours) due to slow dissociation from bone, supports weekly dosing.
Not metabolized; excreted unchanged in urine.
Not metabolized; excreted unchanged by the kidneys.
Renal: 50-60% unchanged via glomerular filtration and active tubular secretion; Fecal: minor, biliary excretion negligible.
Renal: ~50-60% unchanged in urine; biliary/fecal: ~40-50% eliminated via feces, primarily as unchanged drug.
~24% bound to plasma proteins (primarily albumin).
~85-90% bound to plasma proteins, primarily albumin.
Vd: 0.5-1 L/kg, indicating distribution primarily into bone and extracellular fluid.
Vd: 0.9-1.3 L/kg, indicating extensive distribution into bone and soft tissues.
Oral: 0.5-1% under fasting conditions (low due to poor intestinal absorption and high first-pass effect); reduced by 60-90% with food or calcium-containing beverages.
Oral: 0.63% (fasting state); reduced to ~0.4% with food.
Contraindicated if Cr Cl <30 m L/min. If Cr Cl 30-49 m L/min, no adjustment needed. If Cr Cl <30 m L/min, do not use.
Contraindicated if Cr Cl < 30 m L/min. No adjustment for Cr Cl ≥ 30 m L/min. For Cr Cl 30-49 m L/min: avoid use due to lack of data; per FDA labeling, not recommended. For severe renal impairment (Cr Cl < 30): do not use.
No dose adjustment required for mild to moderate hepatic impairment. Not studied in severe hepatic impairment (Child-Pugh C); use caution.
No specific adjustment required for hepatic impairment. Drug is not extensively metabolized by liver; pharmacokinetics unchanged in mild-to-moderate hepatic impairment. No data for severe hepatic impairment.
Safety and efficacy not established in pediatric patients. Not recommended for use in children.
Not approved for pediatric use. Safety and efficacy in patients < 18 years have not been established.
No dose adjustment based on age alone. Monitor renal function. Ensure adequate calcium and vitamin D intake. Same dosing as adults.
No dose adjustment necessary based on age alone. Monitor renal function (Cr Cl) as elderly more likely to have decreased renal function; contraindicated if Cr Cl < 30 m L/min. Ensure adequate calcium and vitamin D intake.
None.
None.
Hypocalcemia must be corrected before therapy,Esophageal irritation and potential for esophageal cancer,Renal impairment (creatinine clearance <30 m L/min) requires dose adjustment or avoidance,Osteonecrosis of the jaw (usually with cancer treatments),Atypical femur fractures with long-term use,Musculoskeletal pain
Hypocalcemia must be corrected before therapy,Renal impairment: not recommended if Cr Cl <30 m L/min,Osteonecrosis of the jaw (ONJ),Atypical femur fractures,Severe musculoskeletal pain
Hypocalcemia,Inability to stand or sit upright for at least 30 minutes,Severe renal impairment (Cr Cl <30 m L/min),Hypersensitivity to risedronate or any component
Hypersensitivity to ibandronate or any component,Hypocalcemia,Inability to stand or sit upright for at least 60 minutes
Calcium, magnesium, iron, and aluminum (e.g., antacids) bind risedronate and reduce absorption. Separate by at least 30 minutes after taking risedronate. Avoid mineral water, dairy products, and calcium-fortified juices within 30 minutes of dosing.
Food, beverages other than plain water, and medications significantly reduce absorption. Avoid all food, drink, and oral medications for at least 60 minutes after dose. For patient convenience, consider once-monthly dosing on the same day each month. Antacids, calcium or iron supplements, and mineral waters should be taken at least 60 minutes after BONIVA.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. Risk cannot be ruled out; use only if clearly needed. First trimester: potential for skeletal effects; second and third trimesters: risk of fetal hypocalcemia and skeletal retardation. Discontinue if pregnancy occurs.
FDA Pregnancy Category C. In pregnant rats, intravenous ibandronate at doses ≥1 mg/kg/day caused fetal skeletal malformations, especially in the skull. In rabbits, no malformations at oral doses up to 10 mg/kg/day but maternal toxicity and reduced fetal weight occurred. Human data: insufficient. Theoretical risk of fetal skeletal abnormalities if used in pregnancy. Avoid use during pregnancy, especially in the second and third trimesters due to potential bone development interference.
Unknown if excreted in human milk. M/P ratio not established. Caution advised; consider alternative treatments during breastfeeding.
Ibandronate is excreted in rat milk at concentrations 0.9 times maternal plasma levels. Human data: unknown. Risk to infant: potential for hypocalcemia and gastrointestinal irritation. Use during breastfeeding only if clearly needed and consider monitoring infant serum calcium. M/P ratio: not established in humans.
No specific pharmacokinetic data during pregnancy. Dose adjustments not routinely recommended; consider discontinuation due to potential fetal risks.
Pharmacokinetic changes in pregnancy (e.g., increased renal clearance, expanded plasma volume) may reduce ibandronate exposure, but no established dose adjustment. Due to teratogenicity and lack of data, avoid use during pregnancy. If inadvertently used, no specific dose adjustment is recommended; however, monitor for hypocalcemia and consider discontinuation. No dosage adjustment postpartum is required.
Actonel (risedronate) is a bisphosphonate for osteoporosis and Paget's disease. Administer on an empty stomach with plain water (not mineral water) at least 30 minutes before the first food, beverage, or other medication. Avoid in Cr Cl <30 m L/min. Monitor for hypocalcemia before treatment. Counsel on atypical femur fractures and osteonecrosis of the jaw (ONJ), especially with dental procedures.
Administer on an empty stomach, first thing in the morning, with a full glass of plain water (6-8 oz). Patient must remain upright for at least 60 minutes after dosing to reduce esophageal irritation. Monitor serum calcium, phosphate, and vitamin D levels prior to initiation and periodically. Contraindicated in severe renal impairment (Cr Cl <30 m L/min). Discontinue if severe musculoskeletal pain occurs.
Take Actonel first thing in the morning with a full glass of plain water (6-8 oz) at least 30 minutes before any food, drink, or other medicine.,Do not lie down for at least 30 minutes after taking to reduce risk of esophageal irritation.,Avoid mineral water, coffee, tea, juice, or calcium-rich beverages as they can reduce absorption.,Report severe bone, joint, or muscle pain; jaw pain or numbness; or signs of hypocalcemia (muscle cramps, tingling).,Maintain adequate calcium and vitamin D intake as directed by your doctor.,If you miss a dose, skip it and resume next morning; do not take two doses on the same day.
Take tablet immediately after waking up with a full glass of plain water, at least 60 minutes before any food, drink, or other medications.,Do not chew, suck, or crush the tablet; swallow it whole.,Stay upright (sitting or standing) for at least 60 minutes after taking the tablet to prevent esophageal irritation.,If you miss a dose, skip it and resume the next morning; do not take two doses on the same day.,Ensure adequate intake of calcium and vitamin D as directed by your physician.,Report sudden thigh or groin pain, or jaw pain with loose teeth, as these may indicate rare adverse effects.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTONEL vs BONIVA, answered by our medical review team.
ACTONEL is a Bisphosphonate that works by Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.. BONIVA is a Bisphosphonate that works by Bisphosphonate that inhibits bone resorption via binding to hydroxyapatite and inhibiting osteoclast activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTONEL and BONIVA depend on the specific clinical indication. These are both Bisphosphonate agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTONEL is: 35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.. The standard adult dose of BONIVA is: 150 mg orally once monthly; 2.5 mg orally once daily also approved but less commonly used. Administer on empty stomach with plain water (6-8 oz) at least 60 minutes before first food, beverage, or other medications. Do not lie down for 60 minutes after administration.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTONEL and BONIVA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTONEL is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. Risk cannot be ruled out; use only. BONIVA is classified as Category C. FDA Pregnancy Category C. In pregnant rats, intravenous ibandronate at doses ≥1 mg/kg/day caused fetal skeletal malformations, especially in the skull. In rabbits, no malformations. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.